PedAM
Pediatric Disease Annotations & Medicines
| Disease | constipation |
| Phenotype | C0022104|irritable bowel |
| Sentences | 57 |
| PubMedID- 22778978 | What do we know about this highly prevalent problem and perhaps the most bothersome symptom for persons with the irritable bowel syndrome, especially of the constipated variety? |
| PubMedID- 23710967 | irritable bowel syndrome (ibs) with constipation was associated with pain in the left flank and patients were less likely to report pain in the right hypochondrium. |
| PubMedID- 26579459 | A lower dose (8 μg) has been approved for irritable bowel syndrome with constipation in woman. |
| PubMedID- 26533504 | Economic burden and quality of life of moderate-to-severe irritable bowel syndrome with constipation (ibs-c) in germany: results from the ibis-c study. |
| PubMedID- 24660576 | Treatment of constipation-predominant irritable bowel syndrome by focusing on the liver in terms of traditional chinese medicine: a meta-analysis. |
| PubMedID- 23835436 | Randomized clinical trial: macrogol/peg 3350 plus electrolytes for treatment of patients with constipation associated with irritable bowel syndrome. |
| PubMedID- 23198977 | Objectives: the aims were: firstly, to review the definition and diagnosis of irritable bowel syndrome with constipation (ibs-c, a subtype of ibs); secondly, to critically assess current therapies for ibs-c with a focus on effectiveness for abdominal pain; and thirdly, to review clinical studies evaluating the efficacy of linaclotide, a therapy recently approved by the us food and drug administration for the treatment of adults with ibs-c and chronic idiopathic constipation and the european medicines agency for the symptomatic treatment of moderate to severe ibs-c in adults, and in development for treatment of ibs-c worldwide. |
| PubMedID- 25726441 | Lower physical energy was found in relation to irritable bowel syndrome with constipation vs. |
| PubMedID- 23859757 | Current interventions for irritable bowel syndrome with constipation tend to target single symptoms of the disorder, with multiple symptom relief only achieved through the use of combinations of therapies. |
| PubMedID- 26294923 | By the nature of altered bowel habits, ibs is classified into subtypes including ibs-c, irritable bowel syndrome with constipation; ibs-d, irritable bowel syndrome with diarrhoea; ibs-m, mixed irritable bowel syndrome (with both diarrhea and constipation >25% of bowel movements); and ibs-a, alternating irritable bowel syndrome (bowel habits often vary over time) [1]. |
| PubMedID- 24433216 | Background: irritable bowel syndrome with constipation (ibs-c) represents a significant burden to patients and healthcare systems due to its prevalence and lack of successful symptomatic resolution with established treatment options. |
| PubMedID- 20863829 | These results suggest that the guanylate cyclase c agonist linaclotide elicits potent pharmacological responses locally in the gastrointestinal tract, and that orally administered guanylate cyclase c agonists may be capable of improving bowel habits in patients suffering from irritable bowel syndrome with constipation and chronic constipation. |
| PubMedID- 24833931 | irritable bowel syndrome with constipation (ibs-c) affects approximately 5% of the population in western countries. |
| PubMedID- 24001336 | Linaclotide-a novel secretagogue in the treatment of irritable bowel syndrome with constipation and chronic idiopathic constipation. |
| PubMedID- 21303430 | The aim of this work was to perform a dose-finding study for lubiprostone for the treatment of constipation with or without irritable bowel syndrome (ibs) in japan. |
| PubMedID- 23641133 | Linaclotide (linzess) for irritable bowel syndrome with constipation and for chronic idiopathic constipation. |
| PubMedID- 22251419 | Background: irritable bowel syndrome with constipation (ibs-c) significantly decreases quality of life and the ability to perform daily living activities. |
| PubMedID- 26028974 | Optimal management of constipation associated with irritable bowel syndrome. |
| PubMedID- 26016701 | irritable bowel syndrome with constipation (ibs-c) and chronic idiopathic constipation (cic) are two common functional gastrointestinal disorders that impair quality of life and pose a significant economic burden to the health care system. |
| PubMedID- 23816770 | Background: irritable bowel syndrome with constipation (ibs-c) and chronic idiopathic constipation (cic) are common functional bowel disorders. |
| PubMedID- 21765950 | Tegaserod is an agonist of the serotonin receptor 5-hydroxytryptamine 4 (5-ht4) and has been used for treating chronic constipation in patients with irritable bowel syndrome and chronic idiopathic constipation [31], [32]. |
| PubMedID- 24252578 | Results: of the 128 consecutive, constipated patients included (84% females, mean age 49.7 +/- 15.5 years) 66 suffered from irritable bowel syndrome with constipation and 62 from functional constipation. |
| PubMedID- 23090647 | Pharmacologic properties, metabolism, and disposition of linaclotide, a novel therapeutic peptide approved for the treatment of irritable bowel syndrome with constipation and chronic idiopathic constipation. |
| PubMedID- 23598923 | Recently, si- ni-san has been shown to alleviate irritable bowel syndrome of the constipation predominant type, decrease palmoplantar perspiration in palmoplantarhidrosis, reduce blood glucose, and improve insulin resistance. |
| PubMedID- PMC4350137 | We conclude that visceral hypersensitivity is likely to be a primary cause of constipation in rats with irritable bowel syndrome with constipation. |
| PubMedID- 24007408 | Introduction: irritable bowel syndrome with constipation (ibs-c) is associated with abdominal pain and infrequent spontaneous bowel movements. |
| PubMedID- 23464519 | irritable bowel syndrome with constipation (ibs-c) and chronic idiopathic constipation (cic) are highly prevalent gastrointestinal disorders associated with health, economical and social problems. |
| PubMedID- 20163375 | Background: renzapride, a 5-hydroxytryptamine type-4 (5-ht(4)) receptor agonist and 5-ht(3) receptor antagonist, has been proposed as a new treatment of irritable bowel syndrome with constipation (ibs-c). |
| PubMedID- 23162373 | Burden of constipation-predominant irritable bowel syndrome (ibs-c) in france, italy, and the united kingdom. |
| PubMedID- 24833940 | Linaclotide: a new option for the treatment of irritable bowel syndrome with constipation and chronic idiopathic constipation in adults. |
| PubMedID- 20050846 | Tegaserod (teg), a 5-hydroxytryptamine type-4 (5-ht(4)) receptor partial agonist, represents a novel treatment for irritable bowel syndrome with constipation and chronic constipation. |
| PubMedID- 24943204 | Background: historically, measures of symptom severity of irritable bowel syndrome with constipation (ibs-c) in clinical trials have not met the evidence requirements described in the fda guidance on patient-reported outcomes (pros), which describes the evidentiary requirements and review criteria for patient-reported outcome measures intended to support product approval or labelling claims. |
| PubMedID- 25545101 | Breath methane correlates with levels of constipation in irritable bowel syndrome (ibs) [24] but methanogens numbers are depleted in ibd [2]. |
| PubMedID- 24693271 | New treatment option for irritable bowel syndrome with constipation and chronic idiopathic constipation. |
| PubMedID- 22847198 | Material/methods: thirty patients with a diagnosis of constipation-predominant irritable bowel syndrome and 30 healthy volunteers were included in the study. |
| PubMedID- 23672677 | In the present issue of neurogastroenterology & motility, the performance of the fda responder endpoint for clinical trials in irritable bowel syndrome with constipation was evaluated using data from two large phase iii clinical trials of linaclotide. |
| PubMedID- 22963061 | Lubiprostone is effective for the treatment of constipation-predominant irritable bowel syndrome, and alosetron (restrictions for use apply in the united states) and tegaserod (available only for emergency use in the united states) are approved for patients with severe symptoms in whom conventional therapy has been ineffective. |
| PubMedID- 21848795 | Epidemiology of functional constipation and comparison with constipation-predominant irritable bowel syndrome: the systematic investigation of gastrointestinal diseases in china (silc). |
| PubMedID- 21324760 | Results: stool form was significantly different in the irritable bowel syndrome patients with diarrhoea or constipation, and bowel movements were more frequent in the irritable bowel syndrome patients than in the healthy subjects. |
| PubMedID- 24684643 | Background: the prevalence of irritable bowel syndrome with constipation (ibs-c) is estimated to be between 4.3% and 5.2% among adults in the united states. |
| PubMedID- 20200325 | Objectives: tegaserod, a partial 5-ht(4) agonist previously approved for treatment of irritable bowel syndrome with constipation and chronic idiopathic constipation, was suspended from us marketing in 2007, based on pooled clinical trial results which contained a signal suggesting increased risk of cardiovascular ischemic events (cvies). |
| PubMedID- 26533542 | Diagnosis and management of moderate-to-severe irritable bowel syndrome with constipation (ibs-c) in germany: results from the ibis-c study. |
| PubMedID- 22444104 | Apart from lubiprostone, treatment of irritable bowel syndrome with constipation is limited to small studies (with poor descriptions of side effects), although lubiprostone and selective serotonin reuptake inhibitors appear safe. |
| PubMedID- 23116208 | Background: treatment options that improve overall symptoms of irritable bowel syndrome with constipation (ibs-c) are lacking. |
| PubMedID- 26555695 | Peptide-based therapeutics have been successfully developed against other molecular targets, as exemplified by the approval of pasireotide (signifor) for the treatment of cushing’s disease [13] and the disulfide-rich linaclotide (linzess®) for the treatment of irritable bowel syndrome with constipation (ibs-c) and idiopathic and chronic constipation [14]. |
| PubMedID- 24351035 | Effect of linaclotide in irritable bowel syndrome with constipation (ibs-c): a systematic review and meta-analysis. |
| PubMedID- 25653859 | Background: optimal clinical trial endpoints for irritable bowel syndrome with constipation (ibs-c) are uncertain. |
| PubMedID- 24812563 | The study of ardatskaia on 30 patients having irritable bowel syndrome with predominance of constipation showed that normoflorin therapy had normalized the intestinal motor activity through changes in microbial flora of the intestines [12]. |
| PubMedID- 21446888 | Introduction: linaclotide is a novel intestinal secretagogue that is in the advanced stages of development for the treatment of irritable bowel syndrome with constipation (ibs-c) and chronic constipation. |
| PubMedID- 21902826 | Our patient also had a history of chronic constipation that was attributed to irritable bowel syndrome, and had been treated with laxatives and prokinetics without lasting success. |
Page: 1 2